LIVONIA, Mich., May 17, 2018 -- Gemphire Therapeutics Inc. (NASDAQ: GEMP), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for cardiometabolic disorders, including non-alcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH) and dyslipidemia, has provided an educational grant to the American Liver Foundation (ALF) to support an upcoming webinar titled "Pediatric Non-Alcoholic Fatty Liver Disease—Yes, It Absolutely Starts in Childhood” on Wednesday, May 23. The American Liver Foundation is the nation’s largest patient advocacy organization for people with liver disease whose mission is to facilitate, advocate and promote education, support and research for the prevention, treatment and cure of liver disease.
“We are delighted to provide an educational grant to help support the ALF’s webinar on pediatric NAFLD and to promote a better comprehension of NAFLD origin and treatment options,” said Lee Golden, M.D., Chief Medical Officer of Gemphire. “We believe that our novel lipid-altering product candidate, gemcabene, has potential to be a highly differentiated treatment for pediatric and adult NAFLD/NASH patients in a market in critical need of better therapeutic options for chronic liver disease.”
|Title: ||Pediatric Non-Alcoholic Fatty Liver Disease—Yes, It Absolutely Starts in Childhood |
|Date: ||Wednesday, May 23 |
|Time: ||8:00am – 9:00am Eastern Time |
|Presenters: ||Dr. Miriam Vos, Assistant Professor of Pediatrics, Emory University School of Medicine; Dr. Saul Karpen, Professor of Pediatrics, Raymond F. Schinazi Distinguished Biomedical Chair, Chief of the Division of Pediatric Gastroenterology, Hepatology and Nutrition at Emory University School of Medicine/Children's Healthcare of Atlanta; Tom Nealon, President & CEO, The American Liver Foundation |
|Registration Link: ||https://register.gotowebinar.com/register/6667421309075083267 |
The hour-long webinar provides an opportunity for general practitioners and pediatricians to receive an in-depth understanding of Pediatric NAFLD. The presenters will be discussing obesity trends and contributing factors, how pediatric and adult NAFLD/NASH perspectives differ from a provider's perspective, key underlying metabolic issues associated with Pediatric NAFLD, current treatment options, future direction of research, and resources available to providers and their patients. Mr. Nealon will be speaking on the webinar along with Dr. Miriam Vos, an Assistant Professor of Pediatrics at Emory University School of Medicine, and Dr. Saul Karpen, a Professor of Pediatrics at Emory University School of Medicine/Children's Healthcare of Atlanta.
Gemphire is currently enrolling patients in a Phase 2a proof-of-concept clinical trial investigating gemcabene as a treatment for pediatric NAFLD. The trial is part of a broader program to develop gemcabene in NAFLD/NASH and is running in parallel with the recently initiated clinical trial investigating gemcabene in familial partial lipodystrophy (FPL). Top line results from the pediatric NAFLD trial are expected in early 2019. More information on both trials can be found at www.clinicaltrials.gov.
About the American Liver Foundation
Founded in 1976, the American Liver Foundation (ALF) is the nation’s largest patient advocacy organization for people with liver disease. ALF reaches more than two million individuals each year with health information, education and support services via its national office, 16 U.S. divisions and an active online presence. Recognized as a trusted voice for people living with liver disease, ALF also operates a toll-free National Helpline (1-800-GO-LIVER); educates patients, policymakers and the public; and provides grants to early-career researchers to help find a cure for all liver diseases. For more information about ALF, visit www.liverfoundation.org.
Gemphire is a clinical-stage biopharmaceutical company that is committed to helping patients with cardiometabolic disorders, including dyslipidemia and NASH. The Company is focused on providing new treatment options for cardiometabolic diseases through its complementary, convenient, cost-effective product candidate gemcabene as add-on to the standard of care, especially statins, that will benefit patients, physicians, and payors. Gemphire’s Phase 2 clinical program is evaluating the efficacy and safety of gemcabene in hypercholesterolemia, including FH and ASCVD, SHTG and NASH/NAFLD. Two trials supporting hypercholesterolemia have been completed under NCT02722408 and NCT02634151. Gemphire has completed recruitment for a clinical trial for SHTG under NCT02944383, and has initiated separate trials for adult NASH and pediatric NAFLD. Please visit www.gemphire.com for more information.
Forward Looking Statements
Any statements in this press release about Gemphire’s future expectations, milestones, goals, plans and prospects, including statements about Gemphire’s financial prospects, future operations and sufficiency of funds for future operations, clinical development of Gemphire’s product candidate, expectations regarding future clinical trials (including the timing of the announcement of top-line results), regulatory developments, submissions and meetings and future expectations and plans and prospects for gemcabene and Gemphire, expectations for the future competitive environment for gemcabene, expectations regarding operating expenses and cash used in operations, and other statements containing the words "believes," "anticipates," "estimates," "expects," "intends," "plans," "predicts," "projects," "targets," "may," "potential," "will," "would," "could," "should," "continue," “scheduled” and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: developments in the capital markets, the success and timing of Gemphire’s regulatory submissions and pre-clinical and clinical trials; regulatory requirements or developments; changes to Gemphire’s clinical trial designs and regulatory pathways; timing of enrollment of patients in our clinical trials; changes in Gemphire’s capital resource requirements; the actions of Gemphire’s competitors; Gemphire’s ability to obtain additional financing; Gemphire’s ability to successfully market and distribute its product candidate, if approved; Gemphire’s ability to obtain and maintain its intellectual property protection; and other factors discussed in the "Risk Factors" section of Gemphire’s annual report, and in other filings Gemphire makes with the SEC from time to time. In addition, the forward-looking statements included in this press release represent Gemphire’s views as of the date hereof. Gemphire anticipates that subsequent events and developments will cause Gemphire’s views to change. However, while Gemphire may elect to update these forward-looking statements at some point in the future, Gemphire specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Gemphire’s views as of any date subsequent to the date hereof.
Andrew McDonald, Ph.D.
LifeSci Advisors, LLC
Jeff Mathiesen, CFO
Gemphire Therapeutics Inc.
Gemphire Therapeutics Inc.